ACBD3

Across TCGA pan-cancer cohorts, ACBD3 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ACBD3 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ACBD3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACBD3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, THYM, and LUSC are the cancer types where ACBD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.059	0.712	<.001	51	view →
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
LUSC	OS	Median	All	0.112	0.776	<.001	36	view →
COAD	OS	Median	All	0.111	0.871	<.001	18	view →
SKCM	DFS	Median	II,III,IV	0.048	0.683	<.001	15	view →
UCEC	DFS	Median	All	0.973	0.828	.019	8	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ACBD3–HNSC (OS)

Open the HNSC breakdown →